Why advanced knee OA often needs two injections, not one

For many patients with Kellgren-Lawrence Grade III or IV knee osteoarthritis, previous injections have helped for a few months and then faded — sometimes barely at all. The reason is not that injectable treatments are ineffective; it is that advanced OA typically damages two anatomically separate compartments at the same time, and most single-injection strategies address only one of them.

The first compartment is the articular cartilage — the shock-absorbing surface that lines the bone ends inside the joint. At Grade III and IV, this surface has thinned, cracked, or worn through entirely in places, removing the structural buffer that allows smooth, pain-free movement under load.

The second compartment is the synovial membrane — the lining that regulates joint fluid and drives the body's inflammatory signalling within the knee. In advanced OA, this lining becomes chronically irritated and dysfunctional, sustaining pain and stiffness through its own independent mechanism, separate from the state of the cartilage above it.

These two processes reinforce each other, but treating one leaves the other unchecked. An injection aimed solely at the cartilage surface does nothing to calm an inflamed synovial lining; equally, a therapy that cushions the lining cannot rebuild the worn structural surface at the bone ends. The case for a dual-injection protocol rests on this straightforward observation: where both compartments are damaged — as is typical by KL Grade III/IV — both compartments need to be addressed, ideally in the same outpatient appointment rather than incompletely or in sequence.

ChondroFiller's role: scaffolding the cartilage surface

Addressing the cartilage compartment falls to ChondroFiller — a CE-marked Class III medical device delivered as an ultrasound-guided outpatient injection rather than a surgical procedure. The material itself is an acellular murine Type I collagen solution: 2.3 mL that self-gels within minutes of contacting the joint, forming a three-dimensional scaffold across the articular surface.

The critical word here is acellular. ChondroFiller contains no cartilage cells of its own. What it provides is a structured biological matrix — a scaffolding that acts as a homing signal, recruiting the patient's own progenitor cells from the surrounding synovium and subchondral bone. Those cells migrate into the scaffold and, over roughly 6–12 months, begin depositing new cartilage matrix. The mechanism is called acellular matrix-induced chondrogenesis: the injection does not deliver a finished repair, it creates the conditions in which the body can produce one. That distinction matters for patient expectations — early weeks bring no dramatic structural change, and meaningful biological remodelling takes the better part of a year.

One feature that makes ChondroFiller particularly applicable at KL Grade III/IV is that the scaffold coats whatever articular surface remains — including bone-on-bone presentations — without requiring a clean, well-defined defect bed. There is no ceiling on defect size, and the injectable route carries no upper age limit, making it a realistic option for active patients in their 60s and 70s as well as younger cases.

On outcomes, the available data show International Knee Documentation Committee (IKDC) scores improving by approximately 30 points over the treatment period in knee patients — a meaningful functional gain. This figure comes from the manufacturer's clinical evaluation report (April 2025) rather than an independent randomised controlled trial, a limitation worth noting when weighing the evidence.

Arthrosamid's role: cushioning the synovial lining

Where ChondroFiller targets the bone ends, the second injection in the protocol addresses an entirely different structure: the synovial membrane. Arthrosamid — a 2.5% cross-linked polyacrylamide hydrogel composed of 97.5% non-pyrogenic water — is injected into the synovial lining rather than onto the cartilage surface. The distinction matters mechanically. Unlike the collagen scaffold, Arthrosamid is non-biodegradable and non-resorbable: it does not break down over time, and it does not prompt the body to generate new structural tissue. Instead, the hydrogel physically integrates into the synovial membrane, providing a permanent mechanical cushion and creating a scaffold into which a fresh layer of synovial lining cells can grow. The goal is sustained reduction of the mechanical and inflammatory burden at the lining — not cartilage restoration, which remains ChondroFiller's separate role.

The strongest published evidence for Arthrosamid in knee OA comes from Bliddal et al. (2024, PMC11064315), a 52-week multi-centre open-label study in 49 patients with a mean age of 70. A single 6 mL injection produced a WOMAC pain reduction of −17.7 points (95% CI −23.1 to −12.4; p<0.0001) sustained through one year, with 62.2% of participants meeting OMERACT-OARSI responder criteria. Stiffness and physical function scores followed a similar trajectory, and no serious adverse events were attributed to the device. It is worth noting that this was an open-label study without a comparator arm, not a randomised controlled trial — a limitation that applies equally to the current evidence base for the dual-injection combination as a whole.

Broader registry and prospective data, including the TACIT trial, suggest that approximately 70–75% of patients exceed the minimal clinically important difference, with symptom relief from a single injection sustained at two to five years in some series. A separate study by Maulana, Cole, and Lee PYF also reported a reduction in patellofemoral bone marrow lesions following a single injection — an intriguing secondary observation that may point to effects beyond simple mechanical cushioning, though this has not yet been established as a primary mechanism.

What a dual-injection appointment actually involves

On the day itself, the appointment is straightforward by the standards of advanced OA intervention. Both products are delivered in a single outpatient session — no general anaesthetic, no theatre admission, no incisions. The patient attends the clinic, the knee is prepared, and the clinician works under continuous ultrasound guidance throughout.

The image guidance is what makes compartment-specific placement reliable. ChondroFiller (2.3 mL) is directed onto the articular surface at the bone ends — the cartilage compartment addressed in the previous section. Arthrosamid (6 mL) is then placed into the synovial membrane lining the joint capsule. These are two anatomically distinct targets within the same joint, and the ultrasound view allows the clinician to confirm positioning in each before proceeding. From the patient's perspective, this is one appointment rather than two separate procedures on separate dates.

The framing throughout is joint preservation ahead of total knee replacement — a non-surgical pathway for a joint that has typically been told surgery is the only remaining option.

On costs, the pricing sits alongside that clinical context: the standard Dual Active Therapy carries a guide cost of approximately £6,000 — substantially less than a joint replacement and without the associated recovery burden. For patients where adding autologous mesenchymal stem cells is clinically appropriate, a Tri-Active option is available at a higher guide cost. Both figures should be confirmed with the treating clinic at assessment, as individual circumstances may affect what is recommended.

Patient selection: who fits this pathway and who does not

The ideal candidate has confirmed KL Grade III or IV knee osteoarthritis with involvement across both compartments — worn articular cartilage at the bone ends and a dysfunctional synovial lining — in a joint that remains mechanically stable. Stability is the critical qualifier for ChondroFiller specifically: a cartilage scaffold can only function as intended if the joint loads symmetrically and predictably. Untreated ligament instability, significant malalignment, or a meniscal deficit actively driving the wear pattern are contraindications — not because the injection cannot be placed, but because a scaffold's environment must allow progenitor cell migration to proceed without continual mechanical disruption undermining the repair process.

Age and defect extent are assessed on their merits rather than applied as fixed cut-offs. The evaluation centres on joint mechanics and imaging findings; neither the number of surfaces involved nor the patient's year of birth determines candidacy in isolation.

For Arthrosamid, the central pre-assessment consideration is permanence: the hydrogel does not resorb over time, and that non-reversible character is part of the informed conversation before proceeding. This is a feature of the decision-making process, not a deterrent to the treatment.

In practice, assessment draws on plain X-ray for KL grading, MRI to characterise the extent of cartilage loss and synovial involvement, biomechanical evaluation, and a review of prior injection history. Whether both components are appropriate — or whether one better fits the clinical picture — is the determination that emerges from that review. The criteria above offer a guide to whether a specialist consultation is worth pursuing; confirming individual suitability requires that assessment in person.

What the evidence shows and what to ask at assessment

The evidence behind this protocol sits at two levels, and patients benefit from understanding both before proceeding.

For each product individually, the evidence is substantive — covered in the earlier sections of this article. Of the two, Arthrosamid carries the larger and more independent published base, with controlled trial data extending to 52 weeks (Bliddal et al., 2024, PMC11064315) and prospective registry follow-up reaching two to five years. ChondroFiller's outcomes are consistent in direction, but the data derive primarily from the manufacturer's own clinical evaluation programme; independent long-term trial evidence has not yet been published.

The combination itself — both products delivered together as a paired protocol — has not been evaluated in a randomised controlled trial or high-quality independent cohort study. The dual-injection approach is grounded in clinical reasoning: each product acts on a different anatomical compartment, each has its own established evidence base, and the logic of combining them follows from the dual-pathology argument described at the start of this article. That reasoning is coherent, but it is reasoning rather than combination trial data, and patients should hold that distinction clearly.

On commissioning: neither product is NHS-funded as of 2026. An NHS study is underway examining how Arthrosamid performs in that setting, though no commissioning timeline has been announced.

Questions worth raising at assessment

Beyond standard candidacy questions — which the preceding sections address — a few things the article itself cannot answer are worth exploring in person:

• If both compartments are affected, what determines whether the standard Dual Active protocol or the Tri-Active option (adding autologous MSCs) is appropriate — and on what evidence is that recommendation based?
• ChondroFiller's repair process develops over six to twelve months; what does the clinic's monitoring protocol look like at that midpoint, and what options exist if the response is partial?
• Given that ChondroFiller's published data are primarily manufacturer-sponsored, what additional evidence or clinical experience is informing its use for your specific pattern and grade of OA?

A specialist assessment at London Cartilage Clinic — covering imaging review, biomechanical evaluation, and prior treatment history — is where these questions are best worked through; appointments can be booked via londoncartilage.com.